These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 38643482)

  • 41. Estrogen receptor mutations and their role in breast cancer progression.
    Alluri PG; Speers C; Chinnaiyan AM
    Breast Cancer Res; 2014 Dec; 16(6):494. PubMed ID: 25928204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
    Busonero C; Leone S; Bartoloni S; Acconcia F
    Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
    Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
    J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen Receptor on the move: Cistromic plasticity and its implications in breast cancer.
    Mayayo-Peralta I; Prekovic S; Zwart W
    Mol Aspects Med; 2021 Apr; 78():100939. PubMed ID: 33358533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KLF17 attenuates estrogen receptor α-mediated signaling by impeding ERα function on chromatin and determines response to endocrine therapy.
    Ali A; Ielciu I; Alkreathy HM; Khan AA
    Biochim Biophys Acta; 2016 Jul; 1859(7):883-95. PubMed ID: 27107895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
    Normanno N; Di Maio M; De Maio E; De Luca A; de Matteis A; Giordano A; Perrone F;
    Endocr Relat Cancer; 2005 Dec; 12(4):721-47. PubMed ID: 16322319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.
    Brett JO; Ritterhouse LL; Newman ET; Irwin KE; Dawson M; Ryan LY; Spring LM; Rivera MN; Lennerz JK; Dias-Santagata D; Ellisen LW; Bardia A; Wander SA
    Oncologist; 2023 Feb; 28(2):172-179. PubMed ID: 36493359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
    Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
    J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
    Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
    Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MLL3 is a de novo cause of endocrine therapy resistance.
    Stauffer KM; Elion DL; Cook RS; Stricker T
    Cancer Med; 2021 Nov; 10(21):7692-7711. PubMed ID: 34581028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
    Jeselsohn R; De Angelis C; Brown M; Schiff R
    Curr Oncol Rep; 2017 May; 19(5):35. PubMed ID: 28374222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
    Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
    Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.
    Gates LA; Gu G; Chen Y; Rohira AD; Lei JT; Hamilton RA; Yu Y; Lonard DM; Wang J; Wang SP; Edwards DG; Lavere PF; Shao J; Yi P; Jain A; Jung SY; Malovannaya A; Li S; Shao J; Roeder RG; Ellis MJ; Qin J; Fuqua SAW; O'Malley BW; Foulds CE
    Oncogene; 2018 Aug; 37(33):4581-4598. PubMed ID: 29748621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
    Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 60. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
    Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
    Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.